Scholar Rock

CompanyUnited States

Scholar Rock develops one asset, in phase 3 (apitegromab in spinal muscular atrophy). Mostly antibody acting on MSTN; based in the United States.

1
Asset
Furthest: Phase 3; 1
Trial: 0
Signals

Pipeline

1

apitegromab
Selective inhibitor of latent myostatin activation preventing muscle atrophy
Phase 3, Antibody, MSTN, spinal muscular atrophy

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms2
Trials1

Papers

The Anti-myostatin Antibody SRK-439 Improves Grip Strength during GLP-1RA Treatment in a Mouse Model of Obesity
ADA Scientific Sessions 2025 abstract, 13 Jun 2025

Updated 10 Oct 2026 · 5 sources